Cargando…
Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
PURPOSE: We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict effectiveness of bevacizumab added to capecitabine and oxaliplatin (CAPEOX) in patients with metastatic colorectal cancer (mCRC). EXPERIMENTAL DESIGN: Patients with mCRC treated with first line CAPEO...
Autores principales: | Boisen, Mogens K., Dehlendorff, Christian, Linnemann, Dorte, Nielsen, Boye S., Larsen, Jim S., Østerlind, Kell, Nielsen, Svend E., Tarpgaard, Line S., Qvortrup, Camilla, Pfeiffer, Per, Holländer, Niels H., Keldsen, Nina, Hansen, Torben F., Jensen, Brita B., Høgdall, Estrid V. S., Jensen, Benny V., Johansen, Julia S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198118/ https://www.ncbi.nlm.nih.gov/pubmed/25329796 http://dx.doi.org/10.1371/journal.pone.0109430 |
Ejemplares similares
-
MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability
por: Boisen, Mogens Karsbøl, et al.
Publicado: (2015) -
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2017) -
A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification
por: Tarpgaard, Line S., et al.
Publicado: (2016) -
miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3(rd) Line Cetuximab and Irinotecan
por: Schou, Jakob V., et al.
Publicado: (2014) -
CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
por: Skougaard, Kristin, et al.
Publicado: (2014)